EHCO: Embolization in Hereditary Coagulopathies

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05629130
Collaborator
Merit Medical Systems, Inc. (Industry)
30
1
1
83.5
0.4

Study Details

Study Description

Brief Summary

This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the Centro de Hemofilia HCFMUSP, after approval by the ethics and research committee.

They will undergo imaging tests (X-rays and Magnetic Resonance of knee, elbow, or ankle), physical, pain, quality of life and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter, Test Timed up and Go, 30 second sit and stand test, Haemophilia - Adult - Quality of Life questionnaire (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score, EQ-5D, numerical rating scale for pain and embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France), until partial vascular stasis and decharacterization of pathological synovial enhancement.

These evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.

Condition or Disease Intervention/Treatment Phase
  • Device: embolization with spherical microparticles embosphere
N/A

Detailed Description

Longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the Centro de Hemophilia do Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, i.e. HC-FMUSP), after approval by the ethics and research committee and registry at the clinical trials.

Patients will be evaluated by imaging (X-rays and Magnetic Resonance of the affected joint, i.e., knee, elbow, and/or ankle); physical and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter of the affected joint(s), Test Timed up and Go, 30 second sit and stand test, Knee Injury and Osteoarthritis Outcome Score (KOOS); quality of life (Haemophilia - adult - quality of life questionnaires (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score (KOOS), EQ-5D; pain measured by numerical rating scale.

Volunteers will be submitted to embolization procedure (superselective embolization of target arteries with spherical microparticles embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint(s), until partial vascular stasis and decharacterization of pathological synovial enhancement.

These evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
longitudinal, prospective study.longitudinal, prospective study.
Masking:
None (Open Label)
Masking Description:
no masking - all treatement
Primary Purpose:
Treatment
Official Title:
Embolization in Hereditary Coagulopathies
Anticipated Study Start Date :
Jan 16, 2023
Anticipated Primary Completion Date :
Dec 31, 2028
Anticipated Study Completion Date :
Dec 31, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: Embolization

embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint, until partial vascular stasis and decharacterization of pathological synovial enhancement.

Device: embolization with spherical microparticles embosphere
embolization of affected joints with spherical microparticles embosphere

Outcome Measures

Primary Outcome Measures

  1. Reduction of synovium thickness by embolization [6 months]

    Measure (in milimeters) changes of synovial thickness in patients with hereditary coagulopathies with arthropathy due to hemarthrosis with MRI (measure synovium thickness)

Secondary Outcome Measures

  1. Reduction of synovitis by embolization [1, 3 12, 24, 36, 48 and 60 months]

    Measure (in milimeters) changes on synovial thickness in patients with hereditary coagulopathies with arthropathy due to hemarthrosis with MRI

  2. Inferior limb strength [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure changes in muscle strength by timed up and go (by time of performance, in seconds).

  3. Inferior limb strength [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure changes in muscle strength of lower limbs by 30 seconds sit to stand test (by number of repetitions)

  4. Balance and fall risk [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure (in seconds, period of time to perform the test) changes in balance and risk of falls by Timed up and go test.

  5. Quality of life of the patient [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure, according to the scale of the questionnaire, changes in quality of life with Haemophilia - Adult - Quality of life Questionnaires (HAEM-A-QoL, 10 dimensions, 0 to 100, being 0 the best health related quality of life)

  6. Quality of life of the patient [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure, according to the scale of the questionnaire, changes in quality of life with Knee Injury and Osteoarthritis Outcome Score (KOOS, 0-100, 100 being the best quality of life).

  7. Quality of life of the patient [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure, according to the scale of the questionnaire, changes in quality of life with by EQ-5D, up to 1, being 1 the best quality of life). Please note: "Since 2009, EQ-5D has been available in three versions: the three-level EQ-5D-3L; the five-level EQ-5D-5L; and a 'youth' adaptation, EQ-5D-Y. Although the EQ is in recognition of the EuroQol group name, the D refers to dimensions, the L signifies level, and the Y stands for youth, the name of the instrument should not be spelled out in this manner as this is inaccurate. Therefore, EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument in general." Brooks R, Boye KS, Slaap B. EQ-5D: a plea for accurate nomenclature. J Patient Rep Outcomes. 2020 Jul 3;4(1):52. doi: 10.1186/s41687-020-00222-9. PMID: 32620995; PMCID: PMC7334333.

  8. Functional capacity [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure (according to the scale of the questionnaire) changes in functional capacity with Functional Independence Score in Hemophilia (FISH score, 0 to 32, 32 being the best result)

  9. Functional capacity [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure (according to the scale of the questionnaire) changes in functional capacity with Functional Independence Score by Knee Injury and Osteoarthritis Outcome Score (KOOS, 0-100, 100 being the best result)

  10. Physical capacity [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure changes in physical capacity by Hemophilia Joint Health Score (HJHS), 0 to 124, 0 being the best result.

  11. Pain of the affected joint [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure changes in pain by Hemophilia Joint Health Score (HJHS, 0-12, 0 being the best result)

  12. Pain of the affected joint [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure changes in pain by numerical rating scale (NRS, 0-10, 0 being no pain and 10 being the worst pain possible)

  13. Pain of the affected joint [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure changes in pain by Knee Injury and Osteoarthritis Outcome Score (KOOS, 0 to 100, 100 being the best result)

  14. Stifness [1, 3, 6, 12, 24, 36, 48, 60 months]

    Measure (0 to 100, 100 being the best result) changes in knee stiffness by Knee Injury and Osteoarthritis Outcome Score (KOOS)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with hereditary coagulopathies with arthropathy (i.e., chronic synovitis due to hemarthrosis), with X-ray and MRI (documenting synovitis) followed up at the Hemophilia Center HC-FMUSP.
Exclusion Criteria:
  • Patients who do not complete the planned assessments

  • Patients who do not accept to continue with the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Instituto de Ortopedia e Traumatologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil 05403-010

Sponsors and Collaborators

  • University of Sao Paulo General Hospital
  • Merit Medical Systems, Inc.

Investigators

  • Principal Investigator: Fabiane E FArias, PT, IOT-HC-FMUSP (Orthopedics Institute - General Hospital- School of Medicine - University of Sao Paulo
  • Study Director: Andre M Assis, MD, PhD, Radiology Insititute, General Hospital, School Medicine, University of São Paulo
  • Study Director: Paula Villaça, MD, PhD, Hematology department, General Hospital, School of Medicine, University of Sâo Paulo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier:
NCT05629130
Other Study ID Numbers:
  • 63452822.1.0000.0068
First Posted:
Nov 29, 2022
Last Update Posted:
Nov 29, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 29, 2022